SUBSCRIBE: eNewsletter
Anti-vascular endothelial growth factor (VEGF) agents—including aflibercept, bevacizumab, and ranibizumab—have ushered in a new era in the treatment of retinal and choroidal neovascularization.
Patient adherence to treatment can sometimes be tricky—especially when out-of-pocket costs are considered.
When it comes to diabetic eye diseases, there are a multitude of potential treatments—but perhaps the “easiest” one for patients is to ensure their A1C levels are under control.1
New research has shown that a longer axial length (AL) may prove protective of incident diabetic retinopathy (DR).1
Proliferative diabetic retinopathy (PDR) is defined by the presence of neovascularization; the use of ultra-widefield (UWF) imaging has shown the distribution of this neovascularization and other diabet
The most consistent means to lower the risk of developing complications from diabetes is for people to maintain good glycemic control.1 The new current criteria for the diagnosis of diabetes now in
Anti-VEGF injections may be associated with acute IOP spikes and chronic IOP rise in patients, and these increases in IOP need to be acknowledged and managed, according to Matthew Schlenker MD, MSc.
A post-hoc analysis of Protocol T from the DRCR Retina Network, which compared anti-vascular endothelial growth factor (VEGF) compounds aflibercept, bevacizumab, and r
According to a 2018 American Eye-Q Survey conducted by the American
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
